+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Radiopharmaceuticals Market By End User, By Radioisotope, By Application, By Type: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 500 Pages
  • April 2024
  • Region: Global
  • Allied Market Research
  • ID: 5835642
Description Jump to:
The radiopharmaceuticals market was valued at $7.9 billion in 2023 and is estimated to reach $21.8 billion by 2033, exhibiting a CAGR of 10.6% from 2024 to 2033. Radiopharmaceuticals are medications that include radioactive versions of chemical elements known as radioisotopes. Depending on the type of radiation they emit, radioisotopes can be used to diagnose or treat a variety of medical diseases. Their uses range from examining and treating various organs, including the brain, heart, kidney, and bone, to the treatment of cancer and hyperthyroidism. Radiopharmaceuticals are administered to patients via injection or orally, and they may be monitored and analyzed using external medical equipment and testing. Most nations have specialized safety measures in place to safeguard patients and health workers from the potential harmful effects of these pharmaceuticals.

The radiopharmaceuticals market is primarily driven by the increase in prevalence of chronic diseases, rise in technological advancements, and growth in applications in diagnostic and therapeutic procedures. As the prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, there is a growing demand for effective diagnostic tools and targeted treatments. Radiopharmaceuticals, with their ability to provide precise imaging and therapeutic options, are increasingly recognized as valuable tools in the fight against these diseases.  In addition, advancements in imaging techniques such as PET and SPECT have significantly improved the accuracy and efficiency of diagnosis, enabling early detection and better management of diseases propels the market growth. Additionally, the emergence of personalized medicine approaches has fueled the demand for radiopharmaceuticals, as they allow for tailored treatments on the basis of individual patient characteristics and molecular targets. However, the high cost associated with the development and production of radiopharmaceuticals can be prohibitive, thus hindering the market growth. This includes expenses related to research, clinical trials, and manufacturing processes, and regulatory compliance. The complex nature of radiopharmaceuticals also requires specialized infrastructure and expertise, further adding to the financial burden. In contrast, ongoing R&D activities for radiopharmaceuticals are increasingly being explored for use in areas such as theranostics, which involves combining diagnostic imaging with targeted therapy that provides lucrative opportunities for the market growth. The radiopharmaceuticals market is segmented on the basis of type, application, radioisotope, end user, and region. On the basis of type, the market is bifurcated into diagnostic, and therapeutic. On the basis of application, the market is classified into cancer, cardiology and others. The cancer segment is further classified into prostate cancer, breast cancer, gastrointestinal cancer, lung cancer, brain tumors, and others. The others segment further bifurcated into Neurological Applications and other applications. On the basis of radioisotope, the market is classified into Iodine I, Gallium 68, Technetium 99m, Fluorine 18, Copper 64, Strontium 89, Yttrium 90, Radium 223, Actinium 225, Lutetium 177, Copper 67, Terbium 161, Zirconium 89, and others. On the basis of end user, the market is categorized into hospitals and clinics, medical imaging centers, and others. On the basis of region, the market is studied across North America (U.S. and Canada), Europe (Germany, UK, France, Spain, Italy, and Rest of Europe), Asia-Pacific (India, China, Australia, Japan, South Korea, Thailand, Malaysia, Indonesia, Singapore, Taiwan, Province Of China, and Rest of Asia-Pacific), and LAMEA (Brazil and Rest of LAMEA). Major key players that operate in the global radiopharmaceuticals market are Bayer AG, Cardinal Health, Eli Lilly and Company, Bracco, Isotopia Molecular Imaging Ltd., Actinium Pharmaceuticals, Inc., Novartis AG, Curium Pharma, Nihon Medi-Physics Co. Ltd., Jubilant Pharmova Limited, Eckert & Ziegler, NorthStar Radioisotopes, The State Atomic Energy Corporation ROSATOM, SOFIE, Lantheus, Telix Pharmaceuticals Limited, Clarity Pharmaceuticals, Fusion Pharmaceuticals Inc., PRECIRIX, ITM Isotope Technologies Munich SE, GE Healthcare, South African Nuclear Energy Corporation (Necsa), and Eczacibasi. Key players operating in the market have adopted agreement, acquisition, expansion, clinical trial, product approval, product upgrade, contract, product development, collaboration, geographical expansion, joint venture, and expansion, as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the radiopharmaceuticals market analysis from 2023 to 2033 to identify the prevailing radiopharmaceuticals market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global radiopharmaceuticals market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By End User

  • Hospitals and Clinics
  • Medical Imaging Centers
  • Others

By Radioisotope

  • Technetium 99m
  • Gallium 68
  • Iodine I
  • Fluorine 18
  • Copper 64
  • Strontium 89
  • Yttrium 90
  • Radium 223
  • Actinium 225
  • Lutetium 177
  • Copper 67
  • Terbium 161
  • Zirconium 89
  • Others

By Application

  • Cancer
  • Type
  • Prostate Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Lung Cancer
  • Brain Tumors
  • Others
  • Cardiology
  • Others
  • Type
  • Neurological Applications
  • Other Applications

By Type

  • Diagnostic
  • Therapeutic

By Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Singapore
  • Taiwan, Province Of China
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Rest of LAMEA
Key Market Players
  • Cardinal Health
  • Eli Lilly and Company
  • Novartis AG
  • Jubilant Pharmova Limited
  • The State Atomic Energy Corporation ROSATOM
  • SOFIE
  • Telix Pharmaceuticals Limited
  • Clarity Pharmaceuticals
  • PRECIRIX
  • NorthStar Medical Radioisotopes
  • South African Nuclear Energy Corporation (Necsa)
  • Bayer AG
  • Bracco
  • Curium Pharma
  • Eckert & Ziegler
  • Lantheus
  • Nihon Medi-Physics Co. Ltd
  • Isotopia Molecular Imaging
  • ITM Isotope Technologies Munich SE
  • GE Healthcare
  • Actinium Pharmaceuticals, Inc.
  • Fusion Pharmaceuticals Inc.
  • Eczacibasi

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate low threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. High intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of chronic diseases
3.4.1.2. Rise in adoption of strategies by key players
3.4.1.3. Rise in R&D activities
3.4.2. Restraints
3.4.2.1. High cost of development and implementation of radiopharmaceuticals
3.4.3. Opportunities
3.4.3.1. Rise in number of pipeline products
CHAPTER 4: RADIOPHARMACEUTICALS MARKET, BY END USER
4.1. Overview
4.1.1. Market size and forecast
4.2. Hospitals and Clinics
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Medical Imaging Centers
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Technetium 99m
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Gallium 68
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Iodine I
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Fluorine 18
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Copper 64
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Strontium 89
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Yttrium 90
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
5.9. Radium 223
5.9.1. Key market trends, growth factors and opportunities
5.9.2. Market size and forecast, by region
5.9.3. Market share analysis by country
5.10. Actinium 225
5.10.1. Key market trends, growth factors and opportunities
5.10.2. Market size and forecast, by region
5.10.3. Market share analysis by country
5.11. Lutetium 177
5.11.1. Key market trends, growth factors and opportunities
5.11.2. Market size and forecast, by region
5.11.3. Market share analysis by country
5.12. Copper 67
5.12.1. Key market trends, growth factors and opportunities
5.12.2. Market size and forecast, by region
5.12.3. Market share analysis by country
5.13. Terbium 161
5.13.1. Key market trends, growth factors and opportunities
5.13.2. Market size and forecast, by region
5.13.3. Market share analysis by country
5.14. Zirconium 89
5.14.1. Key market trends, growth factors and opportunities
5.14.2. Market size and forecast, by region
5.14.3. Market share analysis by country
5.15. Others
5.15.1. Key market trends, growth factors and opportunities
5.15.2. Market size and forecast, by region
5.15.3. Market share analysis by country
CHAPTER 6: RADIOPHARMACEUTICALS MARKET, BY APPLICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Cancer
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.2.4. Cancer Radiopharmaceuticals Market by Type
6.3. Cardiology
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.4.4. Others Radiopharmaceuticals Market by Type
CHAPTER 7: RADIOPHARMACEUTICALS MARKET, BY TYPE
7.1. Overview
7.1.1. Market size and forecast
7.2. Diagnostic
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Therapeutic
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
CHAPTER 8: RADIOPHARMACEUTICALS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by End User
8.2.3. Market size and forecast, by Radioisotope
8.2.4. Market size and forecast, by Application
8.2.5. Market size and forecast, by Type
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by End User
8.2.6.1.2. Market size and forecast, by Radioisotope
8.2.6.1.3. Market size and forecast, by Application
8.2.6.1.4. Market size and forecast, by Type
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by End User
8.2.6.2.2. Market size and forecast, by Radioisotope
8.2.6.2.3. Market size and forecast, by Application
8.2.6.2.4. Market size and forecast, by Type
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by End User
8.3.3. Market size and forecast, by Radioisotope
8.3.4. Market size and forecast, by Application
8.3.5. Market size and forecast, by Type
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by End User
8.3.6.1.2. Market size and forecast, by Radioisotope
8.3.6.1.3. Market size and forecast, by Application
8.3.6.1.4. Market size and forecast, by Type
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by End User
8.3.6.2.2. Market size and forecast, by Radioisotope
8.3.6.2.3. Market size and forecast, by Application
8.3.6.2.4. Market size and forecast, by Type
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by End User
8.3.6.3.2. Market size and forecast, by Radioisotope
8.3.6.3.3. Market size and forecast, by Application
8.3.6.3.4. Market size and forecast, by Type
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by End User
8.3.6.4.2. Market size and forecast, by Radioisotope
8.3.6.4.3. Market size and forecast, by Application
8.3.6.4.4. Market size and forecast, by Type
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by End User
8.3.6.5.2. Market size and forecast, by Radioisotope
8.3.6.5.3. Market size and forecast, by Application
8.3.6.5.4. Market size and forecast, by Type
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by End User
8.3.6.6.2. Market size and forecast, by Radioisotope
8.3.6.6.3. Market size and forecast, by Application
8.3.6.6.4. Market size and forecast, by Type
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by End User
8.4.3. Market size and forecast, by Radioisotope
8.4.4. Market size and forecast, by Application
8.4.5. Market size and forecast, by Type
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by End User
8.4.6.1.2. Market size and forecast, by Radioisotope
8.4.6.1.3. Market size and forecast, by Application
8.4.6.1.4. Market size and forecast, by Type
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by End User
8.4.6.2.2. Market size and forecast, by Radioisotope
8.4.6.2.3. Market size and forecast, by Application
8.4.6.2.4. Market size and forecast, by Type
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by End User
8.4.6.3.2. Market size and forecast, by Radioisotope
8.4.6.3.3. Market size and forecast, by Application
8.4.6.3.4. Market size and forecast, by Type
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by End User
8.4.6.4.2. Market size and forecast, by Radioisotope
8.4.6.4.3. Market size and forecast, by Application
8.4.6.4.4. Market size and forecast, by Type
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by End User
8.4.6.5.2. Market size and forecast, by Radioisotope
8.4.6.5.3. Market size and forecast, by Application
8.4.6.5.4. Market size and forecast, by Type
8.4.6.6. Thailand
8.4.6.6.1. Market size and forecast, by End User
8.4.6.6.2. Market size and forecast, by Radioisotope
8.4.6.6.3. Market size and forecast, by Application
8.4.6.6.4. Market size and forecast, by Type
8.4.6.7. Malaysia
8.4.6.7.1. Market size and forecast, by End User
8.4.6.7.2. Market size and forecast, by Radioisotope
8.4.6.7.3. Market size and forecast, by Application
8.4.6.7.4. Market size and forecast, by Type
8.4.6.8. Indonesia
8.4.6.8.1. Market size and forecast, by End User
8.4.6.8.2. Market size and forecast, by Radioisotope
8.4.6.8.3. Market size and forecast, by Application
8.4.6.8.4. Market size and forecast, by Type
8.4.6.9. Singapore
8.4.6.9.1. Market size and forecast, by End User
8.4.6.9.2. Market size and forecast, by Radioisotope
8.4.6.9.3. Market size and forecast, by Application
8.4.6.9.4. Market size and forecast, by Type
8.4.6.10. Taiwan, Province Of China
8.4.6.10.1. Market size and forecast, by End User
8.4.6.10.2. Market size and forecast, by Radioisotope
8.4.6.10.3. Market size and forecast, by Application
8.4.6.10.4. Market size and forecast, by Type
8.4.6.11. Rest of Asia-Pacific
8.4.6.11.1. Market size and forecast, by End User
8.4.6.11.2. Market size and forecast, by Radioisotope
8.4.6.11.3. Market size and forecast, by Application
8.4.6.11.4. Market size and forecast, by Type
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by End User
8.5.3. Market size and forecast, by Radioisotope
8.5.4. Market size and forecast, by Application
8.5.5. Market size and forecast, by Type
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by End User
8.5.6.1.2. Market size and forecast, by Radioisotope
8.5.6.1.3. Market size and forecast, by Application
8.5.6.1.4. Market size and forecast, by Type
8.5.6.2. Rest of LAMEA
8.5.6.2.1. Market size and forecast, by End User
8.5.6.2.2. Market size and forecast, by Radioisotope
8.5.6.2.3. Market size and forecast, by Application
8.5.6.2.4. Market size and forecast, by Type
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Bayer AG
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Cardinal Health
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Curium Pharma
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Key strategic moves and developments
10.4. Eli Lilly and Company
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.4.7. Key strategic moves and developments
10.5. Jubilant Pharmova Limited
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Lantheus
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.6.7. Key strategic moves and developments
10.7. ITM Isotope Technologies Munich SE
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Key strategic moves and developments
10.8. Telix Pharmaceuticals Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Eckert & Ziegler
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. Bracco
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Key strategic moves and developments
10.11. South African Nuclear Energy Corporation (NECSA)
10.11.1. Company overview
10.11.2. Key executives
10.11.3. Company snapshot
10.11.4. Operating business segments
10.11.5. Product portfolio
10.11.6. Business performance
10.11.7. Key strategic moves and developments
10.12. NorthStar Medical Radioisotopes
10.12.1. Company overview
10.12.2. Key executives
10.12.3. Company snapshot
10.12.4. Operating business segments
10.12.5. Product portfolio
10.12.6. Key strategic moves and developments
10.13. The State Atomic Energy Corporation ROSATOM
10.13.1. Company overview
10.13.2. Key executives
10.13.3. Company snapshot
10.13.4. Operating business segments
10.13.5. Product portfolio
10.13.6. Key strategic moves and developments
10.14. SOFIE
10.14.1. Company overview
10.14.2. Key executives
10.14.3. Company snapshot
10.14.4. Operating business segments
10.14.5. Product portfolio
10.14.6. Key strategic moves and developments
10.15. Isotopia Molecular Imaging
10.15.1. Company overview
10.15.2. Key executives
10.15.3. Company snapshot
10.15.4. Operating business segments
10.15.5. Product portfolio
10.15.6. Key strategic moves and developments
10.16. Fusion Pharmaceuticals Inc.
10.16.1. Company overview
10.16.2. Key executives
10.16.3. Company snapshot
10.16.4. Operating business segments
10.16.5. Product portfolio
10.16.6. Key strategic moves and developments
10.17. Clarity Pharmaceuticals
10.17.1. Company overview
10.17.2. Key executives
10.17.3. Company snapshot
10.17.4. Operating business segments
10.17.5. Product portfolio
10.17.6. Key strategic moves and developments
10.18. Actinium Pharmaceuticals, Inc.
10.18.1. Company overview
10.18.2. Key executives
10.18.3. Company snapshot
10.18.4. Operating business segments
10.18.5. Product portfolio
10.18.6. Business performance
10.18.7. Key strategic moves and developments
10.19. PRECIRIX
10.19.1. Company overview
10.19.2. Key executives
10.19.3. Company snapshot
10.19.4. Operating business segments
10.19.5. Product portfolio
10.19.6. Key strategic moves and developments
10.20. Novartis AG
10.20.1. Company overview
10.20.2. Key executives
10.20.3. Company snapshot
10.20.4. Operating business segments
10.20.5. Product portfolio
10.20.6. Business performance
10.20.7. Key strategic moves and developments
10.21. Nihon Medi-Physics Co. Ltd
10.21.1. Company overview
10.21.2. Key executives
10.21.3. Company snapshot
10.21.4. Operating business segments
10.21.5. Product portfolio
10.22. GE Healthcare
10.22.1. Company overview
10.22.2. Key executives
10.22.3. Company snapshot
10.22.4. Operating business segments
10.22.5. Product portfolio
10.22.6. Business performance
10.22.7. Key strategic moves and developments
10.23. Eczacibasi
10.23.1. Company overview
10.23.2. Key executives
10.23.3. Company snapshot
10.23.4. Operating business segments
10.23.5. Product portfolio
10.23.6. Business performance
10.23.7. Key strategic moves and developments
List of Tables
Table 01. Global Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 02. Radiopharmaceuticals Market for Hospitals and Clinics, by Region, 2023-2033 ($Million)
Table 03. Radiopharmaceuticals Market for Medical Imaging Centers, by Region, 2023-2033 ($Million)
Table 04. Radiopharmaceuticals Market for Others, by Region, 2023-2033 ($Million)
Table 05. Global Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 06. Radiopharmaceuticals Market for Technetium 99M, by Region, 2023-2033 ($Million)
Table 07. Radiopharmaceuticals Market for Gallium 68, by Region, 2023-2033 ($Million)
Table 08. Radiopharmaceuticals Market for Iodine I, by Region, 2023-2033 ($Million)
Table 09. Radiopharmaceuticals Market for Fluorine 18, by Region, 2023-2033 ($Million)
Table 10. Radiopharmaceuticals Market for Copper 64, by Region, 2023-2033 ($Million)
Table 11. Radiopharmaceuticals Market for Strontium 89, by Region, 2023-2033 ($Million)
Table 12. Radiopharmaceuticals Market for Yttrium 90, by Region, 2023-2033 ($Million)
Table 13. Radiopharmaceuticals Market for Radium 223, by Region, 2023-2033 ($Million)
Table 14. Radiopharmaceuticals Market for Actinium 225, by Region, 2023-2033 ($Million)
Table 15. Radiopharmaceuticals Market for Lutetium 177, by Region, 2023-2033 ($Million)
Table 16. Radiopharmaceuticals Market for Copper 67, by Region, 2023-2033 ($Million)
Table 17. Radiopharmaceuticals Market for Terbium 161, by Region, 2023-2033 ($Million)
Table 18. Radiopharmaceuticals Market for Zirconium 89, by Region, 2023-2033 ($Million)
Table 19. Radiopharmaceuticals Market for Others, by Region, 2023-2033 ($Million)
Table 20. Global Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 21. Radiopharmaceuticals Market for Cancer, by Region, 2023-2033 ($Million)
Table 22. Global Cancer Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 23. Radiopharmaceuticals Market for Cardiology, by Region, 2023-2033 ($Million)
Table 24. Radiopharmaceuticals Market for Others, by Region, 2023-2033 ($Million)
Table 25. Global Others Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 26. Global Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 27. Radiopharmaceuticals Market for Diagnostic, by Region, 2023-2033 ($Million)
Table 28. Radiopharmaceuticals Market for Therapeutic, by Region, 2023-2033 ($Million)
Table 29. Radiopharmaceuticals Market, by Region, 2023-2033 ($Million)
Table 30. North America Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 31. North America Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 32. North America Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 33. North America Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 34. North America Radiopharmaceuticals Market, by Country, 2023-2033 ($Million)
Table 35. U.S. Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 36. U.S. Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 37. U.S. Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 38. U.S. Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 39. Canada Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 40. Canada Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 41. Canada Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 42. Canada Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 43. Europe Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 44. Europe Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 45. Europe Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 46. Europe Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 47. Europe Radiopharmaceuticals Market, by Country, 2023-2033 ($Million)
Table 48. Germany Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 49. Germany Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 50. Germany Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 51. Germany Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 52. France Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 53. France Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 54. France Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 55. France Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 56. UK Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 57. UK Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 58. UK Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 59. UK Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 60. Italy Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 61. Italy Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 62. Italy Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 63. Italy Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 64. Spain Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 65. Spain Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 66. Spain Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 67. Spain Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 68. Rest of Europe Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 69. Rest of Europe Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 70. Rest of Europe Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 71. Rest of Europe Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 72. Asia-Pacific Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 73. Asia-Pacific Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 74. Asia-Pacific Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 75. Asia-Pacific Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 76. Asia-Pacific Radiopharmaceuticals Market, by Country, 2023-2033 ($Million)
Table 77. Japan Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 78. Japan Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 79. Japan Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 80. Japan Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 81. China Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 82. China Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 83. China Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 84. China Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 85. India Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 86. India Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 87. India Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 88. India Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 89. Australia Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 90. Australia Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 91. Australia Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 92. Australia Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 93. South Korea Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 94. South Korea Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 95. South Korea Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 96. South Korea Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 97. Thailand Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 98. Thailand Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 99. Thailand Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 100. Thailand Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 101. Malaysia Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 102. Malaysia Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 103. Malaysia Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 104. Malaysia Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 105. Indonesia Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 106. Indonesia Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 107. Indonesia Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 108. Indonesia Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 109. Singapore Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 110. Singapore Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 111. Singapore Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 112. Singapore Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 113. Taiwan, Province of China Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 114. Taiwan, Province of China Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 115. Taiwan, Province of China Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 116. Taiwan, Province of China Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 117. Rest of Asia-Pacific Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 118. Rest of Asia-Pacific Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 119. Rest of Asia-Pacific Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 120. Rest of Asia-Pacific Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 121. LAMEA Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 122. LAMEA Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 123. LAMEA Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 124. LAMEA Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 125. LAMEA Radiopharmaceuticals Market, by Country, 2023-2033 ($Million)
Table 126. Brazil Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 127. Brazil Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 128. Brazil Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 129. Brazil Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 130. Rest of LAMEA Radiopharmaceuticals Market, by End-user, 2023-2033 ($Million)
Table 131. Rest of LAMEA Radiopharmaceuticals Market, by Radioisotope, 2023-2033 ($Million)
Table 132. Rest of LAMEA Radiopharmaceuticals Market, by Application, 2023-2033 ($Million)
Table 133. Rest of LAMEA Radiopharmaceuticals Market, by Type, 2023-2033 ($Million)
Table 134. Bayer AG: Key Executives
Table 135. Bayer AG: Company Snapshot
Table 136. Bayer AG: Product Segments
Table 137. Bayer AG: Product Portfolio
Table 138. Bayer AG: Key Strategies
Table 139. Cardinal Health: Key Executives
Table 140. Cardinal Health: Company Snapshot
Table 141. Cardinal Health: Product Segments
Table 142. Cardinal Health: Product Portfolio
Table 143. Cardinal Health: Key Strategies
Table 144. Curium Pharma: Key Executives
Table 145. Curium Pharma: Company Snapshot
Table 146. Curium Pharma: Product Segments
Table 147. Curium Pharma: Product Portfolio
Table 148. Curium Pharma: Key Strategies
Table 149. Eli Lilly and Company: Key Executives
Table 150. Eli Lilly and Company: Company Snapshot
Table 151. Eli Lilly and Company: Product Segments
Table 152. Eli Lilly and Company: Product Portfolio
Table 153. Eli Lilly and Company: Key Strategies
Table 154. Jubilant Pharmova Limited: Key Executives
Table 155. Jubilant Pharmova Limited: Company Snapshot
Table 156. Jubilant Pharmova Limited: Product Segments
Table 157. Jubilant Pharmova Limited: Product Portfolio
Table 158. Jubilant Pharmova Limited: Key Strategies
Table 159. Lantheus: Key Executives
Table 160. Lantheus: Company Snapshot
Table 161. Lantheus: Product Segments
Table 162. Lantheus: Product Portfolio
Table 163. Lantheus: Key Strategies
Table 164. Itm Isotope Technologies Munich SE: Key Executives
Table 165. Itm Isotope Technologies Munich SE: Company Snapshot
Table 166. Itm Isotope Technologies Munich SE: Product Segments
Table 167. Itm Isotope Technologies Munich SE: Product Portfolio
Table 168. Itm Isotope Technologies Munich SE: Key Strategies
Table 169. Telix Pharmaceuticals Limited: Key Executives
Table 170. Telix Pharmaceuticals Limited: Company Snapshot
Table 171. Telix Pharmaceuticals Limited: Product Segments
Table 172. Telix Pharmaceuticals Limited: Product Portfolio
Table 173. Telix Pharmaceuticals Limited: Key Strategies
Table 174. Eckert & Ziegler: Key Executives
Table 175. Eckert & Ziegler: Company Snapshot
Table 176. Eckert & Ziegler: Product Segments
Table 177. Eckert & Ziegler: Product Portfolio
Table 178. Eckert & Ziegler: Key Strategies
Table 179. Bracco: Key Executives
Table 180. Bracco: Company Snapshot
Table 181. Bracco: Product Segments
Table 182. Bracco: Product Portfolio
Table 183. Bracco: Key Strategies
Table 184. South African Nuclear Energy Corporation (Necsa): Key Executives
Table 185. South African Nuclear Energy Corporation (Necsa): Company Snapshot
Table 186. South African Nuclear Energy Corporation (Necsa): Product Segments
Table 187. South African Nuclear Energy Corporation (Necsa): Product Portfolio
Table 188. South African Nuclear Energy Corporation (Necsa): Key Strategies
Table 189. Northstar Medical Radioisotopes: Key Executives
Table 190. Northstar Medical Radioisotopes: Company Snapshot
Table 191. Northstar Medical Radioisotopes: Product Segments
Table 192. Northstar Medical Radioisotopes: Product Portfolio
Table 193. Northstar Medical Radioisotopes: Key Strategies
Table 194. the State Atomic Energy Corporation Rosatom: Key Executives
Table 195. the State Atomic Energy Corporation Rosatom: Company Snapshot
Table 196. the State Atomic Energy Corporation Rosatom: Product Segments
Table 197. the State Atomic Energy Corporation Rosatom: Product Portfolio
Table 198. the State Atomic Energy Corporation Rosatom: Key Strategies
Table 199. Sofie: Key Executives
Table 200. Sofie: Company Snapshot
Table 201. Sofie: Product Segments
Table 202. Sofie: Product Portfolio
Table 203. Sofie: Key Strategies
Table 204. Isotopia Molecular Imaging: Key Executives
Table 205. Isotopia Molecular Imaging: Company Snapshot
Table 206. Isotopia Molecular Imaging: Product Segments
Table 207. Isotopia Molecular Imaging: Product Portfolio
Table 208. Isotopia Molecular Imaging: Key Strategies
Table 209. Fusion Pharmaceuticals Inc.: Key Executives
Table 210. Fusion Pharmaceuticals Inc.: Company Snapshot
Table 211. Fusion Pharmaceuticals Inc.: Product Segments
Table 212. Fusion Pharmaceuticals Inc.: Product Portfolio
Table 213. Fusion Pharmaceuticals Inc.: Key Strategies
Table 214. Clarity Pharmaceuticals: Key Executives
Table 215. Clarity Pharmaceuticals: Company Snapshot
Table 216. Clarity Pharmaceuticals: Product Segments
Table 217. Clarity Pharmaceuticals: Product Portfolio
Table 218. Clarity Pharmaceuticals: Key Strategies
Table 219. Actinium Pharmaceuticals, Inc.: Key Executives
Table 220. Actinium Pharmaceuticals, Inc.: Company Snapshot
Table 221. Actinium Pharmaceuticals, Inc.: Product Segments
Table 222. Actinium Pharmaceuticals, Inc.: Product Portfolio
Table 223. Actinium Pharmaceuticals, Inc.: Key Strategies
Table 224. Precirix: Key Executives
Table 225. Precirix: Company Snapshot
Table 226. Precirix: Product Segments
Table 227. Precirix: Product Portfolio
Table 228. Precirix: Key Strategies
Table 229. Novartis AG: Key Executives
Table 230. Novartis AG: Company Snapshot
Table 231. Novartis AG: Product Segments
Table 232. Novartis AG: Product Portfolio
Table 233. Novartis AG: Key Strategies
Table 234. Nihon Medi-Physics Co. Ltd.: Key Executives
Table 235. Nihon Medi-Physics Co. Ltd.: Company Snapshot
Table 236. Nihon Medi-Physics Co. Ltd.: Product Segments
Table 237. Nihon Medi-Physics Co. Ltd.: Product Portfolio
Table 238. GE Healthcare: Key Executives
Table 239. GE Healthcare: Company Snapshot
Table 240. GE Healthcare: Product Segments
Table 241. GE Healthcare: Service Segments
Table 242. GE Healthcare: Product Portfolio
Table 243. GE Healthcare: Key Strategies
Table 244. Eczacibasi: Key Executives
Table 245. Eczacibasi: Company Snapshot
Table 246. Eczacibasi: Product Segments
Table 247. Eczacibasi: Product Portfolio
Table 248. Eczacibasi: Key Strategies
List of Figures
Figure 01. Radiopharmaceuticals Market, 2023-2033
Figure 02. Segmentation of Radiopharmaceuticals Market,2023-2033
Figure 03. Top Impacting Factors in Radiopharmaceuticals Market (2023 to 2033)
Figure 04. Top Investment Pockets in Radiopharmaceuticals Market (2024-2033)
Figure 05. Moderate Bargaining Power of Suppliers
Figure 06. Moderate Low Threat of New Entrants
Figure 07. Moderate Threat of Substitutes
Figure 08. High Intensity of Rivalry
Figure 09. Moderate Bargaining Power of Buyers
Figure 10. Global Radiopharmaceuticals Market:Drivers, Restraints and Opportunities
Figure 11. Radiopharmaceuticals Market, by End-user, 2023 and 2033(%)
Figure 12. Comparative Share Analysis of Radiopharmaceuticals Market for Hospitals and Clinics, by Country 2023 and 2033(%)
Figure 13. Comparative Share Analysis of Radiopharmaceuticals Market for Medical Imaging Centers, by Country 2023 and 2033(%)
Figure 14. Comparative Share Analysis of Radiopharmaceuticals Market for Others, by Country 2023 and 2033(%)
Figure 15. Radiopharmaceuticals Market, by Radioisotope, 2023 and 2033(%)
Figure 16. Comparative Share Analysis of Radiopharmaceuticals Market for Technetium 99M, by Country 2023 and 2033(%)
Figure 17. Comparative Share Analysis of Radiopharmaceuticals Market for Gallium 68, by Country 2023 and 2033(%)
Figure 18. Comparative Share Analysis of Radiopharmaceuticals Market for Iodine I, by Country 2023 and 2033(%)
Figure 19. Comparative Share Analysis of Radiopharmaceuticals Market for Fluorine 18, by Country 2023 and 2033(%)
Figure 20. Comparative Share Analysis of Radiopharmaceuticals Market for Copper 64, by Country 2023 and 2033(%)
Figure 21. Comparative Share Analysis of Radiopharmaceuticals Market for Strontium 89, by Country 2023 and 2033(%)
Figure 22. Comparative Share Analysis of Radiopharmaceuticals Market for Yttrium 90, by Country 2023 and 2033(%)
Figure 23. Comparative Share Analysis of Radiopharmaceuticals Market for Radium 223, by Country 2023 and 2033(%)
Figure 24. Comparative Share Analysis of Radiopharmaceuticals Market for Actinium 225, by Country 2023 and 2033(%)
Figure 25. Comparative Share Analysis of Radiopharmaceuticals Market for Lutetium 177, by Country 2023 and 2033(%)
Figure 26. Comparative Share Analysis of Radiopharmaceuticals Market for Copper 67, by Country 2023 and 2033(%)
Figure 27. Comparative Share Analysis of Radiopharmaceuticals Market for Terbium 161, by Country 2023 and 2033(%)
Figure 28. Comparative Share Analysis of Radiopharmaceuticals Market for Zirconium 89, by Country 2023 and 2033(%)
Figure 29. Comparative Share Analysis of Radiopharmaceuticals Market for Others, by Country 2023 and 2033(%)
Figure 30. Radiopharmaceuticals Market, by Application, 2023 and 2033(%)
Figure 31. Comparative Share Analysis of Radiopharmaceuticals Market for Cancer, by Country 2023 and 2033(%)
Figure 32. Comparative Share Analysis of Radiopharmaceuticals Market for Cardiology, by Country 2023 and 2033(%)
Figure 33. Comparative Share Analysis of Radiopharmaceuticals Market for Others, by Country 2023 and 2033(%)
Figure 34. Radiopharmaceuticals Market, by Type, 2023 and 2033(%)
Figure 35. Comparative Share Analysis of Radiopharmaceuticals Market for Diagnostic, by Country 2023 and 2033(%)
Figure 36. Comparative Share Analysis of Radiopharmaceuticals Market for Therapeutic, by Country 2023 and 2033(%)
Figure 37. Radiopharmaceuticals Market by Region, 2023 and 2033(%)
Figure 38. U.S. Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 39. Canada Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 40. Germany Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 41. France Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 42. UK Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 43. Italy Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 44. Spain Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 45. Rest of Europe Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 46. Japan Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 47. China Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 48. India Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 49. Australia Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 50. South Korea Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 51. Thailand Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 52. Malaysia Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 53. Indonesia Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 54. Singapore Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 55. Taiwan, Province of China Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 56. Rest of Asia-Pacific Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 57. Brazil Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 58. Rest of LAMEA Radiopharmaceuticals Market, 2023-2033 ($Million)
Figure 59. Top Winning Strategies, by Year (2021-2024)
Figure 60. Top Winning Strategies, by Development (2021-2024)
Figure 61. Top Winning Strategies, by Company (2021-2024)
Figure 62. Product Mapping of Top 10 Players
Figure 63. Competitive Dashboard
Figure 64. Competitive Heatmap: Radiopharmaceuticals Market
Figure 65. Top Player Positioning, 2023
Figure 66. Bayer AG: Net Sales, 2021-2023 ($Million)
Figure 67. Bayer AG: Research & Development Expenditure, 2021-2023 ($Million)
Figure 68. Bayer AG: Revenue Share by Segment, 2023 (%)
Figure 69. Bayer AG: Revenue Share by Region, 2023 (%)
Figure 70. Cardinal Health: Net Revenue, 2021-2023 ($Million)
Figure 71. Cardinal Health: Revenue Share by Segment, 2023 (%)
Figure 72. Cardinal Health: Revenue Share by Region, 2023 (%)
Figure 73. Eli Lilly and Company: Net Revenue, 2021-2023 ($Million)
Figure 74. Eli Lilly and Company: Revenue Share by Region, 2023 (%)
Figure 75. Jubilant Pharmova Limited: Net Revenue, 2021-2023 ($Million)
Figure 76. Jubilant Pharmova Limited: Revenue Share by Segment, 2023 (%)
Figure 77. Jubilant Pharmova Limited: Revenue Share by Region, 2023 (%)
Figure 78. Lantheus: Net Revenue, 2021-2023 ($Million)
Figure 79. Lantheus: Revenue Share by Segment, 2023 (%)
Figure 80. Telix Pharmaceuticals Limited: Net Revenue, 2021-2023 ($Million)
Figure 81. Telix Pharmaceuticals Limited: Revenue Share by Region, 2023 (%)
Figure 82. Eckert & Ziegler: Net Sales, 2021-2023 ($Million)
Figure 83. Eckert & Ziegler: Revenue Share by Segment, 2023 (%)
Figure 84. Eckert & Ziegler: Revenue Share by Region, 2023 (%)
Figure 85. South African Nuclear Energy Corporation (Necsa): Net Revenue, 2021-2023 ($Million)
Figure 86. Actinium Pharmaceuticals, Inc.: Net Revenue, 2021-2023 ($Million)
Figure 87. Novartis AG: Net Sales, 2021-2023 ($Million)
Figure 88. Novartis AG: Revenue Share by Region, 2023 (%)
Figure 89. GE Healthcare: Net Revenue, 2021-2023 ($Million)
Figure 90. GE Healthcare: Revenue Share by Segment, 2023 (%)
Figure 91. GE Healthcare: Revenue Share by Region, 2023 (%)
Figure 92. Eczacibasi: Net Revenue, 2020-2022 ($Million)

Companies Mentioned

Key Market Players in the Radiopharmaceuticals Market include:
  • Cardinal Health
  • Eli Lilly and Company
  • Novartis AG
  • Jubilant Pharmova Limited
  • The State Atomic Energy Corporation ROSATOM
  • SOFIE
  • Telix Pharmaceuticals Limited
  • Clarity Pharmaceuticals
  • PRECIRIX
  • NorthStar Medical Radioisotopes
  • South African Nuclear Energy Corporation (Necsa)
  • Bayer AG
  • Bracco
  • Curium Pharma
  • Eckert & Ziegler
  • Lantheus
  • Nihon Medi-Physics Co. Ltd
  • Isotopia Molecular Imaging
  • ITM Isotope Technologies Munich SE
  • GE Healthcare
  • Actinium Pharmaceuticals Inc.
  • Fusion Pharmaceuticals Inc.
  • Eczacibasi

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Radiopharmaceutical Theranostics Global Market Report 2024 - Product Image

Radiopharmaceutical Theranostics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Radiopharmaceuticals Global Market Report 2024 - Product Image

Radiopharmaceuticals Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Nuclear Medicine/Radiopharmaceuticals - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Nuclear Medicine/Radiopharmaceuticals - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Radiopharmaceuticals - Global Strategic Business Report - Product Image

Radiopharmaceuticals - Global Strategic Business Report

  • Report
  • 739 Pages
  • Global
From
Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2024-2032 - Product Image

Radiopharmaceuticals Market Report by Product Type, Application, End Use, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.